CorMedix Inc. is a late stage biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath NDA has been accepted and priority review has been granted with a PDUFA date in Q1 of 2021.
Ticker:
CRMD
Exchange:
NYSE American
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Defencath
Development Phase of Primary Product:
NDA Preparation / In Review
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
